7.4 Impact of Prescribing Errors & Medication Problems
Key Takeaways
- Prescribing errors and medication-related problems threaten three patient outcome pillars: safety (harm), efficacy (goal not met), and adherence (regimen not followed)
- Safety impacts include bleeding, hypoglycemia, falls, organ injury, allergic reactions, and preventable hospitalizations
- Efficacy impacts include uncontrolled blood pressure, A1C, lipids, or symptoms when doses are wrong, therapy is duplicated inefficiently, or indicated drugs are missing
- Adherence impacts follow from complexity, side effects, cost of duplicates, and loss of trust after error-related harm
- Technician screening and pharmacist escalation reduce these impacts by catching problems before or during CMR/TMR workflows
Impact of Prescribing Errors & Medication Problems
Quick Answer: Prescribing errors and related medication problems harm patients through safety events (bleeding, falls, organ injury), lost efficacy (uncontrolled chronic disease), and damaged adherence (complexity, fear, cost). MTM technicians who screen and escalate protect all three outcome pillars; ignoring profile red flags allows preventable harm to continue.
Domain 2 explicitly asks you to understand the impact of prescribing errors and medication problems on patients. Recognition is not an academic exercise. Every abnormal dose, duplicate ACE inhibitor, or anticoagulant–NSAID stack you escalate can prevent a hospitalization—and every missed flag can allow one.
Three Outcome Pillars
| Pillar | Question | How prescribing problems show up |
|---|---|---|
| Safety | Is the patient being harmed or at high risk? | Overdose, interaction toxicity, allergy exposure, falls |
| Efficacy | Are treatment goals being met? | Underdose, wrong drug, omitted therapy, conflicting regimens |
| Adherence | Can/will the patient take therapy as intended? | Complex conflicting schedules, side effects from errors, cost of duplicates |
These pillars match the MRP thinking from earlier chapters (indication, effectiveness, safety, adherence). Prescribing defects are a common root cause that feeds all four MRP buckets.
Safety Impacts (Harm and Near Misses)
Safety consequences are the most vivid exam stories:
- Bleeding and stroke tradeoffs: Excess anticoagulation or anticoagulant + NSAID stacks → GI or intracranial bleed. Under-anticoagulation from interacting inducers or wrong DOAC dose → stroke/VTE.
- Hypoglycemia or hyperglycemia: Wrong insulin strength (U-100 vs U-500), duplicate basal regimens, or steroid conflicts without monitoring.
- Cardiovascular instability: Duplicate antihypertensives → syncope and falls; abrupt inappropriate combinations → kidney injury and hyperkalemia.
- CNS depression and falls: Opioid + benzodiazepine prescribing conflicts in older adults → fractures, head injury.
- Organ toxicity: Methotrexate daily instead of weekly → bone marrow suppression and mucositis; acetaminophen duplication → hepatotoxicity.
- Allergic re-exposure: Wrong-drug LASA error reintroduces a documented allergen.
Scenario: An older adult continues both alprazolam and a newly prescribed opioid after dental surgery. One week later they are hospitalized after a nighttime fall. The “impact” is not theoretical—sedation stacking converted a dental script into a major safety event. Earlier technician escalation during profile review could have prompted pharmacist–prescriber coordination and a safer analgesic plan.
Near misses matter too. Catching a daily methotrexate sig before dispensing is a prevented fatality, even if the patient never knew how close they came.
Efficacy Impacts (Goals Not Met)
Not all prescribing problems announce themselves with an ER visit. Many quietly prevent disease control:
| Problem | Efficacy impact |
|---|---|
| Dose too low / wrong strength | Blood pressure, A1C, or TSH remains out of range |
| Wrong drug for indication | Symptoms persist; guidelines-directed therapy never starts |
| Missing indicated therapy | Post-MI patient without statin or antiplatelet → higher event risk |
| Timing errors | Levothyroxine bound by calcium → undertreated hypothyroidism despite “adherent” fills |
| Conflicting therapy | Steroids defeating glycemic plan; inducers defeating anticoagulation |
| Inappropriate continuation of unnecessary drugs | True problems get less attention; polypharmacy obscures what is working |
Duplicate therapy can also impair efficacy indirectly: the patient experiences more side effects, skips doses of the drug that actually helps, and clinics escalate doses on the wrong assumption of nonadherence.
Scenario: Two prescribers unknowingly issue overlapping SSRIs. The patient feels worse (side effects), stops both, and depression returns. The root was duplication; the impact hit safety, efficacy, and adherence together.
Adherence Impacts (The Human Follow-Through)
Prescribing quality shapes whether patients can stick with therapy:
- Complexity: Conflicting meal-timing instructions and multi-drug stacks increase unintentional nonadherence.
- Side effects from errors: Abnormal doses create ADRs; patients stop the drug—and sometimes all drugs from that pharmacy visit.
- Cost: Paying for duplicates drains budgets; patients stretch intervals or abandon therapy.
- Trust: After a serious error-related harm, patients may avoid care or refuse needed medications.
- Mixed messages: Vague “UD” directions leave patients guessing; guessed regimens look like nonadherence in PDC metrics when the real issue was unclear prescribing.
MTM programs measure adherence (PDC) for Star Ratings. Prescribing cleanup—removing duplicates, clarifying schedules, aligning therapy with what the patient can afford—often improves PDC more sustainably than reminder calls alone.
System and Program Impacts (Why Organizations Care)
Patient harm is the primary reason to act, but exam and workplace context also include:
- Preventable hospitalizations and ED visits
- Quality measure failures (adherence, high-risk medication use, CMR completion with unresolved MRPs)
- Malpractice and board risk when alerts are ignored
- Wasted drug spend on duplicates and inappropriate continuations
- Caregiver burden when regimens are unsafe or incomprehensible
Your screening work during PMR/MAP/CMR accuracy checks is quality assurance, not clerical busywork.
Connecting Impact Back to Technician Action
| If you spot… | Likely impact if ignored | Escalate so pharmacist can… |
|---|---|---|
| Abnormal dose / wrong strength | Toxicity or treatment failure | Clarify with prescriber; correct regimen |
| Wrong drug / route | Ineffective or harmful exposure | Stop release; obtain correct order |
| Duplicate class therapy | Additive ADR + cost + confusion | Deprescribe or reconcile intentional combo |
| Major interaction | Bleed, serotonin toxicity, arrhythmia, etc. | Risk-benefit decision; alternative therapy |
| Missing indicated therapy | Preventable progression/events | Recommend initiation per clinical judgment |
The through-line for every section in this chapter is identical: recognize → document → escalate. Impact language on the exam explains why that loop matters. Choosing “release as written to avoid delaying the patient” when a major prescribing defect is visible prioritizes speed over safety and is the wrong answer.
Putting Chapter 7 Together
- Error types tell you what is wrong with the order.
- Inappropriate prescribing and duplicates tell you what should not coexist or continue.
- Interactions and conflicts tell you which combinations create pharmacologic risk.
- Impact tells you what happens to the patient—and why MTM exists.
When you sit for the PTCB MTM Certificate exam, translate case stems into these buckets, then select the response that protects the patient through pharmacist-led resolution. That is Domain 2 patient safety in practice.
Which statement best describes how prescribing errors can affect adherence?
A missed escalation of anticoagulant + NSAID therapy most directly threatens which patient outcome pillar first?
Omitting a high-intensity statin after a recent myocardial infarction primarily illustrates which impact?
Why does the PTCB MTM outline emphasize the impact of prescribing errors and medication problems?